Top

Gepubliceerd in:

01-09-2009 | Editorial

No indication for patent foramen ovale closure in migraine

Auteurs: H. Koppen, G. M. Terwindt, J. Haan, S. F. T. M. de Bruijn, J. J. Bax, M. D. Ferrari

Gepubliceerd in: Netherlands Heart Journal | Uitgave 9/2009

Abstract

The relationship between patent foramen ovale (PFO) and migraine is much debated and controversial. Until recently, evidence on PFO closure to reduce migraine was based upon uncontrolled studies only; nevertheless an increasing number of medical specialists consider PFO closure to be a treatment option. We report on the current evidence of PFO closure in migraine, mainly based on the recently published first prospective double-blind, sham-controlled study.

vorige artikel From concept to product in cardiology

volgende artikel RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists

Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17–20.

Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia. 2008;28:531–40.

Wilmshurst PT, Pearson MJ, Nightingale S, Walsh KP, Morrison WL. Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura. Heart. 2004;90:1315–20.

Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet. 2000;356:1648–51.

Diener HC, Hartung E, Chrubasik J, Evers S, Schoenen J, Eikermann A, et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. Cephalalgia. 2001;21:120–8.

Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008;117:1397–404.

Dowson AJ, Wilmshurst P, Muir KW, Mullen M, Nightingale S. A Prospective, Multicenter, Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Patent Foramen Ovale Closure with the STARFlex Septal Repair Implant to Prevent Refractory Migraine Headaches: the MIST Trial: S61.002. Neurology. 2006;67:185.

Wood S. MIST published; editorial highlights discrepancies, implications for other migraine trials. News Heartwire 2008 March. Online www.medscape.com (21 April 2008).

Qui J. In search of a migraine cure: a matter of heart and mind. Lancet Neurol. 2008;7: 576–77.

10.

Dyer C. News: Doctor is sued for comments on potential migraine device. BMJ. 2008;337:1076.

Titel: No indication for patent foramen ovale closure in migraine
Auteurs: H. Koppen
G. M. Terwindt
J. Haan
S. F. T. M. de Bruijn
J. J. Bax
M. D. Ferrari
Publicatiedatum: 01-09-2009
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Netherlands Heart Journal / Uitgave 9/2009
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI: https://doi.org/10.1007/BF03086276

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 9/2009

Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension

Cardiac resynchronisation therapy and the role of optimal device utilisation

Non-bacterial thrombotic endocarditis in metastatic caecal adenocarcinoma

Cardiopulmonary exercise testing in congenital heart disease: equipment and test protocols

Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism

Marfan syndrome masked by Down syndrome?